ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
New test can predict cancer up to 13 years
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Vince" data-source="post: 19163" data-attributes="member: 843"><p>The Times article requires a login. Is this the source paper?</p><p>NEJM: <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1504030" target="_blank">Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma</a></p><p></p><p>Although the combo therapy is offering statistically significant improvement over the monotherapy (11.5 vs. 2.9 months), the sobering truth is that this breakthrough is merely less appalling in terms of survival time. Furthermore, these meds are admitted as being inflammatory (which is apparently considered unimportant on the failed somatic theory of cancer, but is probably going to cause new cancers on the metabolic theory - if you live that long).</p><p></p><p>The SoC (Standard of Care) for most cancers offers precious little life extension, but does assure that you will be miserable and broke.</p><p></p><p>These advances are sometimes worthwhile. It would be even more interesting to have included a couple of more cohorts in the trial: a group doing KD-R perhaps with exogenous ketones and HBO2 or H2O2 only, and a group doing that with combo.</p></blockquote><p></p>
[QUOTE="Vince, post: 19163, member: 843"] The Times article requires a login. Is this the source paper? NEJM: [URL="http://www.nejm.org/doi/full/10.1056/NEJMoa1504030"]Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma[/URL] Although the combo therapy is offering statistically significant improvement over the monotherapy (11.5 vs. 2.9 months), the sobering truth is that this breakthrough is merely less appalling in terms of survival time. Furthermore, these meds are admitted as being inflammatory (which is apparently considered unimportant on the failed somatic theory of cancer, but is probably going to cause new cancers on the metabolic theory - if you live that long). The SoC (Standard of Care) for most cancers offers precious little life extension, but does assure that you will be miserable and broke. These advances are sometimes worthwhile. It would be even more interesting to have included a couple of more cohorts in the trial: a group doing KD-R perhaps with exogenous ketones and HBO2 or H2O2 only, and a group doing that with combo. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
New test can predict cancer up to 13 years
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top